13200-35-6 Usage
General Description
(2S,6R)-2,6-dimethylpiperidin-4-one is a chemical compound with a piperidin-4-one backbone that contains two chiral centers, resulting in four stereoisomers. This particular stereoisomer has a (2S,6R) configuration, indicating that the substituents are attached to the second and sixth carbon atoms in the piperidin ring in a specific orientation. The compound is a ketone, characterized by a carbonyl group located at the fourth carbon in the piperidine ring. It is used as a building block in organic synthesis and can serve as a precursor for the preparation of various pharmaceuticals, agrochemicals, and other organic compounds. Its unique structure and reactivity make it a valuable compound in the field of organic chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 13200-35-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,3,2,0 and 0 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 13200-35:
(7*1)+(6*3)+(5*2)+(4*0)+(3*0)+(2*3)+(1*5)=46
46 % 10 = 6
So 13200-35-6 is a valid CAS Registry Number.
13200-35-6Relevant articles and documents
-
Mannich
, p. 323,351 (1934)
-
AMINOPYRIMIDINES AS ALK INHIBITORS
-
Paragraph 0172; 0173, (2018/03/25)
The present disclosure provides compounds represented by Formula (I): and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1a, R1b, R2a, R2b, R3, R4, R5, R6, and R7 are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to inhibition of ALK such as cancer.
Novel kinase inhibitors
-
Paragraph 0325-0327, (2017/08/02)
The present invention relates to a novel kinase inhibitor useful as a medicine for tumor, nerve disorder and mental illness. The purpose of the present invention is to provide a compound having improved blood-aqueous barrier penetrability to neurodegenerative diseases that cancer spreads to brain or progresses in brain. To this end, provided is a compound represented by chemical formula 1 or a pharmaceutically allowable salt thereof.COPYRIGHT KIPO 2017
